Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Episodic CandClus2
2025-521470-34-00Phase 3Authorised
- Sponsor
- Helse Bergen HF, St. Olavs Hospital HF
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, triple-blind trial of candesartan in Cluster Headache (CH), sponsored by Helse Bergen HF, St. Olavs Hospital HF. Planned start Nov 2025; status: authorised.
02
Drugs
candesartan
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2025-521470-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521470-34-00.